Adamax
Experimental relative of Semax, with almost no published research
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Experimental peptide related to Semax, with practically no published research of its own. The dosing patterns in circulation are transpositions from Semax made by the community — which is an extrapolation, not data. It appears in nasal and subcutaneous routes.
Quick reference
- Route
- Nasal and subcutaneous.
- Dosing basis
- Transposed from Semax by the community — there is no pharmacokinetics of its own.
- Status
- Not approved. Almost no direct published research.
Community SubQ titration pattern
| Weeks | Daily dose | Volume | Insulin units |
|---|---|---|---|
| Weeks 1-2 | 300 mcg (0.3 mg) | 0.09 mL | 9 units |
| Weeks 3-4 | 500 mcg (0.5 mg) | 0.15 mL | 15 units |
| Weeks 5-6 | 750 mcg (0.75 mg) | 0.23 mL | 23 units |
| Weeks 7-8 | 1000 mcg (1.0 mg) | 0.30 mL | 30 units |
Adamax Nasal Spray vs SubQ Injection
| Topic | Intranasal Adamax | SubQ Adamax |
|---|---|---|
| Format | Ready-made spray, nasal drops, or powder mixed for nasal use | Freeze-dried vial mixed with bacteriostatic water |
| Measurement | Depends on the listed concentration and amount delivered by each spray | Depends on vial strength, BAC-water volume, and U-100 syringe units |
| Common community pattern | Small amounts, discussed 1× or more per day | A few hundred micrograms per day with some titration schedules |
| Direct Adamax evidence | No route-specific study | No route-specific study |
| Main practical issue | Different spray products may deliver different amounts per pump | Mixing errors can change the amount contained in each syringe unit |
| Can the doses be converted? | No tested conversion exists | No tested conversion exists |
Adamax Peptide Benefits: Claims vs Evidence
| Claim | Where the claim comes from | Adamax evidence |
|---|---|---|
| Improved focus | User reports and comparison with Semax | No direct Adamax study |
| Better memory or learning | Semax and ACTH-fragment research | No direct Adamax study |
| Higher BDNF activity | Semax studies in cells and animals | Not confirmed for Adamax |
| Longer duration than Semax | Chemical theory and seller descriptions | No direct half-life comparison |
| Better brain entry | Claims about the added adamantane-related modification | No Adamax absorption or brain-distribution study |
| Neuroprotective effects | Parent-peptide and animal research involving Semax | Not confirmed for Adamax |
Adamax vs Semax: What Is the Difference?
| Feature | Adamax | Semax |
|---|---|---|
| What it is | Modified Semax-related synthetic peptide | Synthetic ACTH(4–10)-related peptide |
| Direct published research | No direct studies found | Animal, laboratory, and some human research exists |
| Measured half-life | Not established | Semax timing has been studied more, but results depend on route and study design |
| Claimed duration | Often claimed to last longer | Usually described as shorter acting |
| Proof of longer action | No direct comparison | Not applicable |
| Common format | Nasal product or freeze-dried vial | Most closely linked with intranasal use |
| FDA status | Not FDA-approved | Not FDA-approved in the United States |
| Main evidence limit | Almost every benefit claim is indirect | Research exists, but it does not prove that Adamax has the same effects |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.